SCHEMBL7067157

SCHEMBL7067157

CC1(C)OB(B2OCCO2)OC1(C)C

nearest known ligand 0.31

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 1/20 0.31
LAP3 P28838 1/20 0.31
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL28884396 0.97
SCHEMBL15916667 0.80 ANPEP (0.40) ANPEPLAP3
SCHEMBL7260295 0.79
Dioxane SCHEMBL25176962 0.79 TTR (0.38) ANPEPLAP3MAPK1
SCHEMBL5199147 0.77 ANPEP (0.38) ANPEPLAP3
SCHEMBL298586 0.73
SCHEMBL18056974 0.73 ANPEP (0.32) ANPEPLAP3
SCHEMBL16136329 0.71 ANPEP (0.31) ANPEPLAP3
SCHEMBL22664164 0.71 ANPEP (0.31) ANPEPLAP3
SCHEMBL18400901 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1056751-A4 BORONIC COMPOUNDS COMMW SCIENT IND RES ORG (AU) 2003-01-22 EP claimed
US-20020052522-A1 Boronic compounds COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION 2002-05-02 US claimed
US-6346639-B1 Boronic compounds THE COMMONWEALTH OF AUSTRALIA COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) 2002-02-12 US claimed
EP-1056751-A1 BORONIC COMPOUNDS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2000-12-06 EP claimed
WO-1999033845-A1 BORONIC COMPOUNDS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 1999-07-08 WO claimed
EP-4720060-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2026-04-08 EP disclosed
EP-4709720-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2026-03-18 EP disclosed
EP-3858833-B9 AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREOF AND USE THEREOF TRANSTHERA SCIENCES NANJING INC (CN) 2026-03-11 EP disclosed
EP-3858833-B1 AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREOF AND USE THEREOF TRANSTHERA SCIENCES NANJING INC (CN) 2025-10-22 EP disclosed
US-12377080-B2 Allosteric EGFR inhibitors and methods of use thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-08-05 US disclosed
US-12291534-B2 Aminonorbornane derivative and manufacture method therefor and use thereof TRANSTHERA SCIENCES (NANJING), INC. (CN) 2025-05-06 US disclosed
WO-2025029075-A1 NOVEL BIPHENYL DERIVATIVE AS PD-L1 INHIBITOR (주)아이랩 2025-02-06 WO disclosed
US-11020380-B2 Therapeutic compounds CELGENE QUANTICEL RESEARCH, INC. (US) 2021-06-01 US disclosed
US-20200163946-A1 THERAPEUTIC COMPOUNDS CELGENE QUANTICEL RESEARCH, INC. (US) 2020-05-28 US disclosed
US-10617680-B2 Therapeutic compounds CELGENE QUANTICEL RESEARCH, INC. (US) 2020-04-14 US disclosed
US-20180296543-A1 THERAPEUTIC COMPOUNDS CELGENE QUANTICEL RESEARCH, INC. 2018-10-18 US disclosed
US-8354429-B2 Inhibitors of human immunodeficiency virus replication GILEAD SCIENCES, INC. (US) 2013-01-15 US disclosed
US-8354429-B2 Inhibitors of human immunodeficiency virus replication GILEAD SCIENCES, INC. (US) 2013-01-15 US disclosed
US-20100311735-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2010-12-09 US disclosed
US-20100311735-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11020380-B2 Therapeutic compounds EP300, BRD4, BRD3 ANPEP 4336/4885LAP3 3979/4885MAPK1 967/4885
US-12291534-B2 Aminonorbornane derivative and manufacture method therefor and use thereof BTK, LCK, SYK ANPEP 1935/4885LAP3 3213/4885MAPK1 511/4885
US-12377080-B2 Allosteric EGFR inhibitors and methods of use thereof EGFR, ERBB2, ERBB3 ANPEP 1373/4885LAP3 2419/4885MAPK1 353/4885
US-20200163946-A1 THERAPEUTIC COMPOUNDS EP300, BRD4, BRD3 ANPEP 4336/4885LAP3 3979/4885MAPK1 967/4885
US-20180296543-A1 THERAPEUTIC COMPOUNDS EP300, BRD4, BRD3 ANPEP 4336/4885LAP3 3979/4885MAPK1 967/4885
US-20020052522-A1 Boronic compounds NR0B2, NR4A1, NR0B1 ANPEP 3956/4885LAP3 4667/4885MAPK1 1901/4885
US-10617680-B2 Therapeutic compounds EP300, BRD4, BRD3 ANPEP 4336/4885LAP3 3979/4885MAPK1 967/4885
US-20100311735-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION RTF2, REV1, POLR1E ANPEP 2863/4885LAP3 3455/4885MAPK1 1742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.